Trastuzumab of benefit in HER2-positive breast cancer

The pharmaceutical journal Group

首页> 外文期刊>The pharmaceutical journal >Trastuzumab of benefit in HER2-positive breast cancer

【24h】

Trastuzumab of benefit in HER2-positive breast cancer

机译：曲妥珠单抗对HER2阳性乳腺癌的益处

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The pharmaceutical journal》 |2001年第7142期|共1页
作者
The pharmaceutical journal Group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype? [J] . Kim Jisun, Pareja Fresia, Weigelt Britta, Journal of the National Cancer Institute . 2017,第2期

机译：预测HER2阳性乳腺癌中的曲妥珠单抗益处：是内在亚型吗？
2. [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：[FAM-]曲妥珠单抗（T-DXD; DS-8201A）与预先接受曲妥珠单抗和紫杉烷的患者（T-DXD; DS-8201A）对受试者的ADO-TRASTUZUMAB emtansine（T-DM1）与HER2-阳性，不可切除的和/或转移性乳腺癌：阶段3 ，随机试验（Destiny-Breast03）
3. Atezolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer: Safety and biomarker outcomes from a multi-cohort Phase Ib study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：atezolizumab与Trastuzumab Omtansine或用曲妥珠单抗和腹腔癌患者的患者与海莫霉素和atezolizumab与海莫霉素和环磷酰胺组合，在Her2阴性乳腺癌中：来自多队阶段IB研究的安全和生物标志物结果
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Gut Microbiota and Trastuzumab Response in HER2-Positive Breast Cancer [D] . Di Modica, Martina. 2020

机译：肠道微生物群和胸瘤反应在Her2阳性乳腺癌中
6. IGF1R Protein Expression is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2-positive Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831 [O] . Monica M. Reinholz, Beiyun Chen, Amylou C. Dueck, -1

机译：来自北部中部癌症治疗组（联合）辅助曲妥珠单抗试验N9831的早期HER2阳性乳腺癌中IGF1R蛋白表达与并发曲妥珠单抗的差异性没有相关性
7. Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype? [O] . Jisun Kim, Fresia Pareja, Britta Weigelt, 2016

机译：在HER2阳性乳腺癌中预测曲妥珠单抗中的益处：是在内在亚型吗？

Trastuzumab of benefit in HER2-positive breast cancer

著录项

相似文献

相关主题

期刊订阅